Serum 90K/Mac-2 binding protein (Mac-2BP) as a response predictor to peginterferon and ribavirin combined treatment in Hcv chronic patients

Palma A. Iacovazzi, Raffaele Cozzolongo, Elsa Lanzillotta, Stefania Frisullo, Vito Guerra, Mario Correale

Research output: Contribution to journalArticle

Abstract

90K/Mac-2BP glycoprotein is involved in the immune defense against a variety of neoplasms and viral infections, modulating the activity of several effectors such as natural killer cells. Quite interestingly, 90K/Mac-2BP is associated to a poor response to interferon (IFN) α in hepatitis C virus (HCV) infected patients. Here, in 70 consecutive HCV chronic patients, we have evaluated 90K basal levels as a response predictor to combined therapy with Peginterferon and Ribavirin. We have found higher 90K levels in genotype 1/4 than in genotype 2/3 (p = 0.006) and in 62.5% of non-responders than in 20% of responders (p <0.001). Genotype 1/4, higher 90K and gamma glutamyl transferase (γGT) levels resulted independently associated to a status of refractoriness to therapy. Consequently, evaluation of 90K serum levels seems to be a promising useful marker of response to combined therapy in HCV disease.

Original languageEnglish
Pages (from-to)687-700
Number of pages14
JournalImmunopharmacology and Immunotoxicology
Volume30
Issue number4
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Ribavirin
Viruses
Hepacivirus
Carrier Proteins
Genotype
Virus Diseases
Serum
Transferases
Natural Killer Cells
Interferons
Glycoproteins
Therapeutics
Neoplasms

Keywords

  • 90K/Mac-2BP
  • Hepatitis C
  • Treatment

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology
  • Toxicology

Cite this

Serum 90K/Mac-2 binding protein (Mac-2BP) as a response predictor to peginterferon and ribavirin combined treatment in Hcv chronic patients. / Iacovazzi, Palma A.; Cozzolongo, Raffaele; Lanzillotta, Elsa; Frisullo, Stefania; Guerra, Vito; Correale, Mario.

In: Immunopharmacology and Immunotoxicology, Vol. 30, No. 4, 12.2008, p. 687-700.

Research output: Contribution to journalArticle

@article{f82f3db556af4576a657b02ab9abe957,
title = "Serum 90K/Mac-2 binding protein (Mac-2BP) as a response predictor to peginterferon and ribavirin combined treatment in Hcv chronic patients",
abstract = "90K/Mac-2BP glycoprotein is involved in the immune defense against a variety of neoplasms and viral infections, modulating the activity of several effectors such as natural killer cells. Quite interestingly, 90K/Mac-2BP is associated to a poor response to interferon (IFN) α in hepatitis C virus (HCV) infected patients. Here, in 70 consecutive HCV chronic patients, we have evaluated 90K basal levels as a response predictor to combined therapy with Peginterferon and Ribavirin. We have found higher 90K levels in genotype 1/4 than in genotype 2/3 (p = 0.006) and in 62.5{\%} of non-responders than in 20{\%} of responders (p <0.001). Genotype 1/4, higher 90K and gamma glutamyl transferase (γGT) levels resulted independently associated to a status of refractoriness to therapy. Consequently, evaluation of 90K serum levels seems to be a promising useful marker of response to combined therapy in HCV disease.",
keywords = "90K/Mac-2BP, Hepatitis C, Treatment",
author = "Iacovazzi, {Palma A.} and Raffaele Cozzolongo and Elsa Lanzillotta and Stefania Frisullo and Vito Guerra and Mario Correale",
year = "2008",
month = "12",
doi = "10.1080/08923970802278177",
language = "English",
volume = "30",
pages = "687--700",
journal = "Immunopharmacology and Immunotoxicology",
issn = "0892-3973",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Serum 90K/Mac-2 binding protein (Mac-2BP) as a response predictor to peginterferon and ribavirin combined treatment in Hcv chronic patients

AU - Iacovazzi, Palma A.

AU - Cozzolongo, Raffaele

AU - Lanzillotta, Elsa

AU - Frisullo, Stefania

AU - Guerra, Vito

AU - Correale, Mario

PY - 2008/12

Y1 - 2008/12

N2 - 90K/Mac-2BP glycoprotein is involved in the immune defense against a variety of neoplasms and viral infections, modulating the activity of several effectors such as natural killer cells. Quite interestingly, 90K/Mac-2BP is associated to a poor response to interferon (IFN) α in hepatitis C virus (HCV) infected patients. Here, in 70 consecutive HCV chronic patients, we have evaluated 90K basal levels as a response predictor to combined therapy with Peginterferon and Ribavirin. We have found higher 90K levels in genotype 1/4 than in genotype 2/3 (p = 0.006) and in 62.5% of non-responders than in 20% of responders (p <0.001). Genotype 1/4, higher 90K and gamma glutamyl transferase (γGT) levels resulted independently associated to a status of refractoriness to therapy. Consequently, evaluation of 90K serum levels seems to be a promising useful marker of response to combined therapy in HCV disease.

AB - 90K/Mac-2BP glycoprotein is involved in the immune defense against a variety of neoplasms and viral infections, modulating the activity of several effectors such as natural killer cells. Quite interestingly, 90K/Mac-2BP is associated to a poor response to interferon (IFN) α in hepatitis C virus (HCV) infected patients. Here, in 70 consecutive HCV chronic patients, we have evaluated 90K basal levels as a response predictor to combined therapy with Peginterferon and Ribavirin. We have found higher 90K levels in genotype 1/4 than in genotype 2/3 (p = 0.006) and in 62.5% of non-responders than in 20% of responders (p <0.001). Genotype 1/4, higher 90K and gamma glutamyl transferase (γGT) levels resulted independently associated to a status of refractoriness to therapy. Consequently, evaluation of 90K serum levels seems to be a promising useful marker of response to combined therapy in HCV disease.

KW - 90K/Mac-2BP

KW - Hepatitis C

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=54949086764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54949086764&partnerID=8YFLogxK

U2 - 10.1080/08923970802278177

DO - 10.1080/08923970802278177

M3 - Article

C2 - 18720164

AN - SCOPUS:54949086764

VL - 30

SP - 687

EP - 700

JO - Immunopharmacology and Immunotoxicology

JF - Immunopharmacology and Immunotoxicology

SN - 0892-3973

IS - 4

ER -